



# Medicine: cabozantinib (brand name: Cabometyx<sup>®</sup>) for advanced renal cell carcinoma - resubmission

Ipsen Ltd UK

## What is cabozantinib used for?

Cabozantinib is used to treat renal cell carcinoma (RCC), which is the most common type of kidney cancer in adults. It starts in the lining of tiny tubes in the kidneys that are involved in filtering the blood and making urine. In advanced RCC the cancer has spread beyond the kidneys to other parts of the body.

## How does cabozantinib work?

Cabozantinib works by blocking the action of over-active proteins (called tyrosine kinases) in cancer cells. These proteins are involved in the growth of cancer cells and the new blood vessels needed to supply them. By blocking their action, cabozantinib can help slow the growth and spread of the cancer cells.

### What has SMC said?

SMC has not recommended cabozantinib for the treatment of adults with advanced renal cell carcinoma who have not had any treatment yet and who have a moderate to high risk of the cancer getting worse quickly.



## Why has SMC said this?

SMC looks at how well new medicines work compared with current treatments available in Scotland and in relation to how much they will cost to buy and administer (for example, if the medicine has to be given at a clinic or side effects have to be monitored).

SMC carefully considers every new medicine to make sure it benefits patients and is considered to be an acceptable use of the limited resources in NHSScotland. When SMC assesses a medicine it takes account of the needs of all patients in NHSScotland, not just those who may be treated with the medicine under consideration.

To do this SMC consider the following:

- Clinical trial and economic evidence from the company that makes the medicine.
- Advice from healthcare professionals about any benefits of the new medicine compared to current treatment, along with how the new medicine is likely to be used.
- Information from patient groups about the potential impact of the medicine on patients and carers.

After careful consideration, SMC decided the evidence from the company was not strong enough to be certain that cabozantinib offers value for money to NHSScotland. This was despite applying extra flexibility as cabozantinib is a medicine for an end of life condition.

### What does SMC's decision mean for me?

Cabozantinib should not normally be prescribed on the NHS in Scotland for use as described above. Your healthcare professional should talk to you about other treatment options available to you. If your healthcare professional believes that cabozantinib would be of benefit, they can make a request to prescribe it for you. All health boards have procedures in place to consider these requests. For further information see:

Medicines in Scotland: What's the right treatment for me?

[www.healthcareimprovementscotland.org/medicinesbooklet.aspx](http://www.healthcareimprovementscotland.org/medicinesbooklet.aspx)



### More information

The organisations below can provide more information and support for people with kidney cancer and their families. SMC is not responsible for the content of any information provided by external organisations.

#### Kidney Cancer Scotland



<http://www.kidneycancerscot.org>



0141 428 3494

#### Kidney Cancer Support Network



<http://www.kcsn.org.uk>



01209 890326

#### Kidney Research UK



<http://www.kidneyresearchuk.org>



0300 303 1100

You can find out more about cabozantinib in the European public assessment report (EPAR) summary for the public by searching for the medicine name on the European Medicines Agency (EMA) website.

 <http://www.ema.europa.eu>

**Date advice published:** 11 February 2019

**SMC No:** (SMC2136)